Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04330586
Recruitment Status : Recruiting
First Posted : April 1, 2020
Last Update Posted : September 16, 2020
Sponsor:
Information provided by (Responsible Party):
Woo Joo Kim, Korea University Guro Hospital

Brief Summary:
According to In vitro studies, ciclesonide showed good antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some cases were reported for the clinical effectiveness of ciclesonide in the treatment of COVID-19, there is no clinical trial to evaluate the antiviral effect on the reduction of viral load in patients with COVID-19. In this study, we aimed to investigate whether ciclesonide alone or in combination with hydroxychloroquine could eradicate SARS-CoV-2 from respiratory tract earlier in patients with mild COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Ciclesonide Metered Dose Inhaler [Alvesco] Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This multicenter study is an open-labelled, randomized clinical trial for 1:1 ratio of ciclesonide or control arm (standard care)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
Actual Study Start Date : April 1, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ciclesonide

Arm Intervention/treatment
Experimental: Ciclesonide
Ciclesonide 320ug oral inhalation q12h for 14 days
Drug: Ciclesonide Metered Dose Inhaler [Alvesco]
Ciclesonide 320ug oral inhalation q12h for 14 days

No Intervention: Control
Standard care without ciclesonide



Primary Outcome Measures :
  1. Rate of SARS-CoV-2 eradication at day 14 from study enrollment [ Time Frame: Hospital day 14 ]
    Viral load


Secondary Outcome Measures :
  1. Rate of SARS-CoV-2 eradication at day 7 from study enrollment [ Time Frame: Hospital day 7 ]
    Viral load

  2. Time to SARS-CoV-2 eradication (days) [ Time Frame: Hospital day 1, 4, 7, 10, 14, 21 ]
    Viral load

  3. Viral load area-under-the-curve (AUC) reduction versus control [ Time Frame: Hospital day 1, 4, 7, 10, 14, 21 ]
    Viral load change

  4. Time to clinical improvement (days) [ Time Frame: Up to 28 days ]
    Resolution of all systemic and respiratory symptoms for ≥2 consecutive days

  5. Proportion of clinical failure [ Time Frame: Up to 28 days ]
    ICU admission, mechanical ventilation or death


Other Outcome Measures:
  1. Safety and tolerability of study drug [ Time Frame: Up to 28 days ]
    Number of adverse events, proportion of early discontinuance



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with mild COVID-19 (NEWS scoring system 0-4)
  • Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)

Exclusion Criteria:

  • Hypoxia (SaO2 <95%)
  • Unable to take oral medication
  • Unable to use inhaler
  • Pregnancy or breast feeding
  • Immunocompromising conditions
  • Moderate/severe renal dysfunction : creatinine clearance (CCL) < 30 mL/min
  • Moderate/severe liver dysfunction: AST or ALT > 5 times upper normal limit
  • Asthma or chronic obstructive lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04330586


Contacts
Layout table for location contacts
Contact: Joon Young Song, MD, PhD 82-2-2626-3052 infection@korea.ac.kr

Locations
Layout table for location information
Korea, Republic of
Korea University Guro Hospital Recruiting
Seoul, Korea, Republic of
Contact: Joon Young Song, MD    82-2-2626-1104    infection@korea.ac.kr   
Contact: Ji Yun Noh, MD       jynoh@korea.ac.kr   
Sponsors and Collaborators
Korea University Guro Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Woo Joo Kim, Professor, Korea University Guro Hospital
ClinicalTrials.gov Identifier: NCT04330586    
Other Study ID Numbers: KUMC-COVID-19
First Posted: April 1, 2020    Key Record Dates
Last Update Posted: September 16, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Woo Joo Kim, Korea University Guro Hospital:
SARS-CoV-2
Ciclesonide
Viral load
Coronavirus
Additional relevant MeSH terms:
Layout table for MeSH terms
Ciclesonide
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents